The discovery of TNF-alpha: a historical perspective

Main Article Content

Natasa Kustrimovic
Daniela Gallo
Andrea De Lerma Barbaro
Eliana Piantanida
Lorenzo Mortara
Maria Laura Tanda


tumor necrosis factor, cytokine, cancer treatment, TNF-alfa


Tumor necrosis factor (TNF), also known as TNF-alpha (TNF-α), is a pleiotropic pro-inflammatory cytokine that exerts multiple biologic effects. The research journey into the role of TNF has been a roller- coaster ride filled with ups and downs and it is still ongoing. At its discovery, huge expectations were laid upon this cytokine going so far that the cloning of human TNF, which had been achieved and published in 1984, was examined in the general press around the globe, and its therapeutic potential in cancer treatment was welcomed as the opening of a new era in cancer treatment. Nevertheless, the first clinical studies did not yield the expected results and it seemed for a moment that the glory of TNF was ending. But the discovery of the pro-inflammatory effect of TNF changed the course of the research journey of this cytokine. TNF is a highly pleiotropic cytokine and accordingly, it plays a pivotal role in many physiological functions, and is involved in a wide variety of pathological conditions. TNF has become a major target in chronic inflammatory diseases, and its neutralization have delivered the first insights into the development of a novel category of pharmaceuticals, the “biological drugs”.

Abstract 81 | PDF Downloads 20


1. Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the bacillus prodigiosus). Proc R Soc Med 1909; 3:1–48.
2. Kolb WP, Granger GA. Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin. Proc Natl Acad Sci USA 1968; 61:1250-5.
3. Ruddle NH, Waksman BH. Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. 3. Analysis of mechanism. J Exp Med 1968; 128:1267-79.
4. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72:3666-70.
5. Aggarwal BB, Kohr WJ, Hass PE, et al. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 1985; 260:2345-54.
6. Aggarwal BB, Henzel WJ, Moffat B, Kohr WJ, Harkins RN. Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem 1985; 260:2334-44.
7. Aggarwal BB, Moffat B, Harkins RN. Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 1984; 259:686-91.
8. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 1985; 318:665-7.
9. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487-501.
10. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312:724-729.
11. Gray PW, Aggarwal BB, Benton CV, et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 1984; 312:721-4.
12. Marmenout A, Fransen L, Tavernier J, et al. Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor. Eur J Biochem 1985; 152:515-22.
13. Fransen L, Müller R, Marmenout A, et al. Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression. Nucleic Acids Res 1985; 13:4417-29.
14. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 115:1-20.
15. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012; 119:651-65.
16. Ware CF. Tumor Necrosis Factors. Encyclopedia of Cancer (Second Edition). Editor(s): Joseph R. Bertino. pp 475-89; 2002.
17. Zhang H, Shi N, Diao Z, Chen Y, Zhang Y. Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future. Genes Dis 2020; 8:38-47.
18. Wang JL, Yin WJ, Zhou LY, et al. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis. Clin Rheumatol 2020; 39:769-778.
19. de Lisle D. Traité sur le vice cancereux. Paris: Couturier fils. 1774.
20. Oelschlaeger TA. Bacteria as tumor therapeutics? Bioeng Bugs 2010; 1:146-7.
21. Busch W. VII. Verhandlungen artzlicher gesellschaften. Berl Klin Wochenschr 1868; 5:137-8.
22. Fehleisen V. VI. Ueber die zuchtung der erysipelkokken auf kunstlichem nahrboden und ihre uebertragbarkeit auf den menschen. Dtsch Med Wochenschr 1882; 8:553-4.
23. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893; 105:487–511.
24. Roger H. Contribution a l’etude experimentale du streptocoque de l’erysipele. Rev de Med 1892; 12:929-59.
25. Coley WB. Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and bacillus prodigiosus. Am J Med Sci 1906; 131:375–430.
26. Starnes CO. Coley's toxins in perspective. Nature 1992; 357:11-2.
27. Leech PN. Erysipelas and Prodigiosus toxins (Coley). JAMA 1934; 103:1067–9.
28. Nauts HC, Swift WE, Coley BL. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res 1946; 6:205-16.
29. Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl 1953; 276:1-103.
30. Gratia A, Linz R. Le phenomenene de Schwartzman dans le sarcome du cobaye. C R Soc Biol 1931; 108:427–8.
31. Shear MJ, Perrault A. Chemical treatment of tumors. IX. Reactions of mice with primary subcutaneous tumors to injection of a hemorrhage- producing bacterial polysaccharide. J Natl Cancer Inst1944; 44:461–76.
32. O’Malley WE, Achinstein B, Shear MJ. Action of bacterial polysaccharide on tumours. II. Damage of sarcoma 37 by serum of mice treated with serratia marcescens polysaccharide, and induced tolerance. J Natl Cancer Inst 1962; 29:1169–75.
33. Algire GH, Legallais FY, Anderson BF. Vascular reactions of normal and malignant tissues in vivo. V. The role of hypotension in the action of a bacterial polysaccharide on tumors. J Natl Cancer Inst 1952; 12:1279-95.
34. Green S, Carswell E, Old LJ, et al. "Mechanisms of endotoxin-induced tumor hemorrhagic necrosis," Proc Am Assoc Cancer Res 1974; 15:139.
35. Hibbs JB Jr, Lambert LH Jr, Remington JS. Control of carcinogenesis: a possible role for the activated macrophage. Science 1972; 177:998-1000.
36. Keller R. Cytostatic elimination of syngeneic rat tumor cells in vitro by nonspecifically activated macrophages. J Exp Med 1973; 138:625-44.
37. Kelker HC, Oppenheim JD, Stone-Wolff D, et al. Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin. Int J Cancer 1985; 36:69-73.
38. Bringman TS, Aggarwal BB. Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes. Hybridoma 1987; 6:489-507.
39. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264:11974-80.
40. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990; 265:1531-6.
41. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9:361-71.
42. Old LJ. Tumor necrosis factor (TNF). Science 1985; 230:630-2.
43. Helson L, Green S, Carswell E, Old LJ. Effect of tumour necrosis factor on cultured human melanoma cells. Nature 1975; 258:731-2.
44. Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 1983; 80:5397-401.
45. Haranaka K, Satomi N, Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and hetero-transplanted human tumors in nude mice. Int J Cancer 1984; 34:263-7.
46. Brouckaert PG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W. In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer 1986; 38:763-9.
47. Teng MN, Park BH, Koeppen HK, Tracey KJ, Fendly BM, Schreiber H. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA 1991; 88:3535-9.
48. Berendt MJ, North RJ, Kirstein DP. The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity. J Exp Med 1978; 148:1550-9.
49. Berendt MJ, North RJ, Kirstein DP. The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity. J Exp Med 1978; 148:1560-9.
50. McIntosh JK, Mulé JJ, Merino MJ, Rosenberg SA. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha. Cancer Res 1988; 48:4011-7.
51. McIntosh JK, Mulé JJ, Krosnick JA, Rosenberg SA. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice. Cancer Res 1989; 49:1408-14.
52. Balkwill FR, Lee A, Aldam G, et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 1986; 46:3990-3.
53. Talmadge JE, Phillips H, Schneider M, Rowe T, Pennington R, Bowersox O, Lenz B. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988; 48:544-50.
54. Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 1988; 48:650-3.
55. Nawroth P, Handley D, Matsueda G, De Waal R, Gerlach H, Blohm D, Stern D. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med 1988; 168:637-47.
56. Mantovani A, Dejana E. Cytokines as communication signals between leukocytes and endothelial cells. Immunol Today 1989; 10:370-5.
57. Balza E, Mortara L, Sassi F, et al. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res 2006; 12:2575-82.
58. Mortara L, Balza E, Sassi F, et al. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan. Eur J Immunol 2007; 37:3381-92.
59. Balza E, Carnemolla B, Mortara L, et al. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNF alpha. Int J Cancer 2010; 127:101-10.
60. Balza E, Zanellato S, Poggi A, Reverberi D, Rubartelli A, Mortara L. The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells. Eur J Immunol 2017; 47:743-53.
61. Mortara L, Orecchia P, Castellani P, Borsi L, Carnemolla B, Balza E. Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine. Cancer Med 2013; 2:478-87.
62. Balza E, Carnemolla B, Orecchia P, Rubartelli A, Poggi A, Mortara L. Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency. Curr Med Chem 2020; 27:4233-48.
63. Mortara L, Benest AV, Bates DO, Noonan DM. Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours? Curr Opin Pharmacol 2017; 35:66-74.
64. Croce M, Meazza R, Orengo AM, et al. Sequential immunogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clin Cancer Res 2005; 11:735-42.
65. Ongaro T, Matasci M, Cazzamalli S, et al. A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors. J Biotechnol 2019; 291:17-25.
66. Spriggs D, Imamura K, Rodriguez C, Horiguchi J, Kufe DW. Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc Natl Acad Sci USA 1987; 84:6563-6.
67. Orosz P, Echtenacher B, Falk W, Rüschoff J, Weber D, Männel DN. Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 1993; 177:1391-8.
68. Im SY, Ko HM, Kim JW, et al. Augmentation of tumor metastasis by platelet-activating factor. Cancer Res 1996; 56:2662-5.
69. Beissert S, Bergholz M, Waase I, et al. Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. Proc Natl Acad Sci U S A 1989; 86:5064-8.
70. Naylor MS, Malik ST, Stamp GW, Jobling T, Balkwill FR. In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur J Cancer 1990; 26:1027-30.
71. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993; 91:2194-206.
72. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006; 25:409-16.
73. Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004; 4:314-20.
74. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987; 329:630-2.
75. Malik ST, Griffin DB, Fiers W, Balkwill FR. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer 1989; 44:918-25.
76. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184:1397-411.
77. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5:828-31.
78. Tomita Y, Yang X, Ishida Y, et al. Spontaneous regression of lung metastasis in the absence of tumor necrosis factor receptor p55. Int J Cancer 2004; 112:927-33.
79. Kitakata H, Nemoto-Sasaki Y, Takahashi Y, Kondo T, Mai M, Mukaida N. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res 2002; 62:6682-7.
80. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45.
81. Premoli P, Tanda ML, Piantanida E, et al. Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study. J Endocrinol Invest 2020; 43:109-116.
82. Vilcek J, Palombella VJ, Henriksen-DeStefano D, et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 1986; 163:632-43.
83. Erard F, Corthesy P, Smith KA, Fiers W, Conzelmann A, Nabholz M. Characterization of soluble factors that induce the cytolytic activity and the expression of T cell growth factor receptors of a T cell hybrid. J Exp Med 1984; 160:584-99.
84. Fiers W, Brouckaert P, Guisez Y, et al. Recombinant interferon-gamma and its synergism with tumour necrosis factor in the human and mouse systems. In: H. Schellekens and W.E. Stewart (eds.), The biology of the interferon system 1985; pp. 241-8, Elsevier, Amsterdam (1986).
85. Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA Jr. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol 1985; 135:2069-73.
86. Torti FM, Dieckmann B, Beutler B, Cerami A, Ringold GM. A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science 1985; 229:867-9.
87. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869-71.
88. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985; 316:552-4.
89. Collins T, Lapierre LA, Fiers W, Strominger JL, Pober JS. Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,Bantigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci USA 1986; 83:446-50.
90. Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA Jr. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 1986; 136:1680-7.
91. Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, et al. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. Int J Mol Sci 2021; 22:2719.
92. van Loo G, Bertrand MJM. Death by TNF: a road to inflammation. Nat Rev Immunol 2023; 23:289-303.
93. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47:2986-9.
94. Kimura K, Taguchi T, Urushizaki I, et al. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987; 20:223-9.
95. Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 1988; 62:2467-71.
96. Fràter-Schröder M, Risau W, Hallmann R, Gautschi P, Böhlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84:5277-81.
97. Malik ST, Naylor MS, East N, Oliff A, Balkwill FR. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 1990; 26:1031-4.
98. Schall TJ, Lewis M, Koller KJ, et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990; 61:361-70.
99. Gray PW, Barrett K, Chantry D, Turner M, Feldmann M. Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci USA 1990; 87:7380-4.
100. Loetscher H, Pan YC, Lahm HW, et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990; 61:351-9.
101. Heller RA, Song K, Villaret D, et al. Amplified expression of tumor necrosis factor receptor in cells transfected with Epstein-Barr virus shuttle vector cDNA libraries. J Biol Chem 1990; 265:5708-17.
102. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52-60.
103. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105-10.

Most read articles by the same author(s)